Created On: 2020-07-15
Record Count: 6
- Central Nervous System
- Drug Discovery
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245927
Patent Rights shall mean: (a) the United States and international patents listed.
US Patent Application #10/108,195 titled Methods and Products related to FGF Dimerization
(b) the United States and international patent applications and/or provisional applications listed and the resulting patents; (c) any patent applications resulting from the provisional applications listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed and of such patent applications that result from the provisional applications listed, to the extent the claims are directed to subject matter specifically described in the patent applications listed, and the resulting patents; (d) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents described in (a), (b), and (c) above; and (e) international (non-United States) patent applications and provisional applications filed after the effective date and the relevant international equivalents to divisionals, continuations, continuation-in-part applications and continued prosecution applications of the patent applications to the extent the claims are directed to subject matter specifically described in the patents or patent applications referred to in (a), (b), (c), and (d) above, and the resulting patents.
Licensed Process shall mean any process that, absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights or which uses a Licensed Product.
United States Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'
International (non-U.S.) Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'
WO Patent Application Serial No US02/09517, Filed on March 27, 2002
Entitled: METHODS AND PRODUCTS RELATED TO FGF DIMERIZATION
patents pertain to a novel molecule for treatment of neurological disorders, including stroke.
IPSCIO Record ID: 274908
In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the MPG Patent Rights in the Field with the scope as set forth (hereinafter the â€œOther Diagnostic Licensesâ€, or the 'Other Diagnostic Licensees', as applicable).
Licensed Products shall mean any product (I) that, or the development, manufacture, use or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which is developed or manufactured by using a Licensed Process or that, when used, practices a Licensed Process.
MPG Patent Rights shall mean: (Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter â€œMPGâ€œ), a German non-profit scientific research organisation)
the patent applications filed by MPG listed, and the resulting patents,
any subsequent patent applications in any jurisdiction claiming the same priority date and directed to the same subject matter as the patent application listed, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed, and the resulting patents, and
any patents resulting from reissues, reexaminations (and their relevant international equivalents) of the patents described in (a) and (b) above.
International Patent applications filed by MPG entitled 'Small expressed RNA molecules (MicroRNA molecules)'
Licensed Service shall mean any service (I) that, or the performance or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the MPG Patent Rights, or (ii) which, when performed, uses a Licensed Process or a Licensed Product.
(a) Companys internal and collaborative research and development purposes, and
(b) Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.
IPSCIO Record ID: 299252
Licensed Technology shall mean all information and materials proprietary to Licensor, including designs, technical information, know how, knowledge, data, specifications, test results and other information relating to the Licensed Patents and disclosed by Licensor to Licensee on the date of this Agreement or during the term hereof.
Licensed Patents shall mean the inventions embodied in the patent applications and patents identified in hereof, together with all divisionals, continuations, reissues, and foreign counterparts of such applications or patents.
Licensor holds certain title and rights in a joint invention on the alpha 7 nicotinic receptor agonists and the JAK pathway with Licensee, specifically:
Case #016-02: 'Methods and Compositions for Treatment of Central Nervous System Disorders'
Patent Status: Provisional U.S. patent application prepared by Licensee, complete with data and claims.
Neurodegeneration refers to the progressive atrophy and loss of function of neurons, which is present in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
IPSCIO Record ID: 273247
Licensed Patent Rights shall mean the Patent Rights, the Non-exclusive Patent Rights and Research Patent Rights.
Research Patent Rights shall mean any United States and/or non-United States patent or patent applications and all substitutions, divisions, continuations, continuations-in-part, reissues, reexaminations and extensions thereof that are owned or otherwise controlled by the Licensor and that cover the Know-how and/or Research Know-how developed prior to or during the course of the Research Program.
Patent Rights shall mean: The patent application set forth, designated as exclusive; Any non-United States patent applications claiming priority from the patent application referred to; Claims of United States continuation-in-part applications, and of the resulting patents; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents.
Exclusive Patent Rights: New Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method.
Non-exclusive Patent Rights: A general procedure for the preperative scale systhesis of protected Ca (functionalysed alkyl) amino acids suitable for solid phase synthesis.
Exclusive Know-How: All new developments, now in existence or to be developed pursuant to the Research Program.
Non-Exclusive Know-How: The novel building units described in Agreement and a process for the preparation of compounds described in the Agreement consisting of a multistep reaction procedure.
Non-Exclusive Patent Rights shall mean the provisional patent application set forth in this Agreement designated as non-exclusive; Any United States utility patent application and non-United States patent applications based, in whole or in part, on the provisional patent application set forth; The United States and non-United States patents issued from the applications referred to; Claims of United States continuation-in-part applications, and of the resulting patents, which are based on the subject matter specifically described; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents described.
IPSCIO Record ID: 282853
U.S. Patent Applications Ser. No. 08/263,607, filed June 20, 1994, Ser. Nos. 08/458,061 and 08/458,085, both filed June 1, 1995, all entitled 'Administration of Pirenzipine, Methyl Scopolamine, and Other Muscarinic Receptor Antagonists for Treatment of Lipid Metabolism Disorders'
U.S. Patent Applications Ser. No. 08/271, 881, filed July 7, 1994, Ser. Nos. 08/458,960 and 08/459,114, both filed June 2, 1995, all entitled 'Method of Regulating Immune Function'
U.S. Patent Application Ser. No. 08/475,296, filed June 7, 1995, entitled 'Method of Inhibiting Neoplastic Disease in Mammals'
U.S. Provisional Patent Application Ser. No. 60/001,428, filed July 25, 1995, entitled 'Neuroendocrine Therapy for Inhibiting Neoplastic Disease'
The term Product shall mean any article, device, composition, method or service, the importation, manufacture, use, offer for sale or sale of which, absent the licenses granted herein, would infringe an enforceable claim of any Licensed Patent.
Neoplastic diseases are conditions that cause tumor growth â€” both benign and malignant. Benign tumors are noncancerous growths. They usually grow slowly and can't spread to other tissues.
IPSCIO Record ID: 227262
Licensed Patent Rights means (a) the patent applications set forth, (b) United States patents issued from the applications listed and from divisionals and continuations of these applications and any reissues of such United States patents, (c) claims of continuation-in-part applications and patents directed to subject matter specifically described in the applications listed, and (d) claims of all foreign patent applications, patents, and other intellectual property which are directed to the subject matter specifically described in the United States patents and/or patent applications listed.
Certain Licensed Patent Rights include:
1. United States provisional patent application no. 60/374,557 filed on April 22, 2002 entitled 'Atomic Coordinates (3D Structure) of the N-Terminal Portion of the Immature HIV-1 Gag Polyprotein' (attorney docket no. UMBC2392MS):
2. United States provisional patent application no. 60/375,852 filed on April 25, 2002 entitled 'Atomic Coordinates (3D Structure) of the N-Terminal Portion of the Immature HIV-1 Gag Polyprotein' <attorney docket no. UMBC2392MS-2): and
3. United States provisional patent application no. 60/404,043 filed on August 16, 2002 entitled 'Method of Identifying Anti-Viral Compounds' <attorney docket no.
Licensed Intellectual Property means Licensed Know-How and Licensed Patent Rights.